ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,537Medicare Part D Prescriptions Filled, Including Refills

Rank: 75 out of 337

$405K Total Retail Price of All Prescriptions

Rank: 103 out of 337

407 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
22% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 407 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

8% of this provider’s 407 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 8,149 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$42 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
SIMVASTATIN 400 362 1 1
LISINOPRIL 373 333 2 2
METOPROLOL TARTRATE 323 285 3 6
OMEPRAZOLE 286 256 4 4
ATENOLOL 280 257 5 10
MELOXICAM 274 249 6 54
LEVOTHYROXINE SODIUM 268 216 7 5
FUROSEMIDE 238 205 8 8
AMLODIPINE BESYLATE 236 212 9 3
ATORVASTATIN CALCIUM 214 213 10 7
DOXAZOSIN MESYLATE 198 179 11 68
HYDROCHLOROTHIAZIDE 195 187 12 9
METOPROLOL SUCCINATE 182 175 13 21
ALLOPURINOL 169 142 14 28
PRAVASTATIN SODIUM 164 145 15 14
METFORMIN HCL 157 134 16 12
LOVASTATIN 138 106 17 24
ALENDRONATE SODIUM 122 105 18 19
WARFARIN SODIUM 117 93 19 11
LOSARTAN POTASSIUM 112 111 20 15
TAMSULOSIN HCL 106 105 21 25
HYDROCODONE-ACETAMINOPHEN 103 66 S3 22 13
GLIPIZIDE ER 101 95 23 69
ZOLPIDEM TARTRATE 93 74 24 23
AZITHROMYCIN 91 86 25 51
QUINAPRIL HCL 86 75 26 50
SPIRIVA 81 80 27 43
TRIAMTERENE-HCTZ 81 67 27 39
VERAPAMIL ER 80 70 29 77
CITALOPRAM HBR 76 65 30 17
ISOSORBIDE MONONITRATE ER 70 58 31 70
CLOPIDOGREL 67 67 32 42
FLUOXETINE HCL 66 40 33 57
PREDNISONE 65 64 34 40
DIGOXIN 63 54 35 58
DIOVAN 61 61 36 26
TRAZODONE HCL 60 48 37 16
FLUTICASONE PROPIONATE 60 44 37 34
ALPRAZOLAM 56 56 39 78
NAMENDA 56 56 39 35
SYNTHROID 54 54 41 41
ENALAPRIL MALEATE 53 53 42 37
CRESTOR 53 49 42 29
RANITIDINE HCL 51 34 44 30
DILTIAZEM 24HR ER 50 47 45 76
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.